VCAM1 and stroke disorder: The goal of this study is to test the ability of this RNA-based VCAM-1-aptamer to target CECs in vivo after stroke as well as evaluate effectiveness for treating ischemic stroke using a murine transient middle cerebral artery occlusion (tMCAO) model.